發明
中華民國
106124625
I 639430
醫藥組合物用於製備治療胃癌藥物的用途
中國醫藥大學
2018/11/01
1. A method of treating gastric cancer, comprising administering to a person in need thereof exemestane (6-methylenandrosta-1,4-diene-3,17-dione). 2. The method of claim 1 further comprising the antecedent step of identifying the person as having gastric cancer and/or being in need of exemestane therapy. 3. The method of claim 1 or 2 further comprising the subsequent step of monitoring status of the gastric cancer or a biomarker thereof, such as androgen receptor (AR), progesterone receptor (PR), estrogen receptor 1; ERα (ESR1) and estrogen receptor 2; ERβ (ESR2). 4. The method according to claim 1, 2 or 3, wherein the gastric cancer is HER2-negative. 5. The method according to claim 1, 2, 3, or 4, wherein the person is a gastrectomy patient. 6. The method according to claim 1, 2, 3 or 4, wherein the person is contraindicated for gastrectomy. 7. Use of exemestane (6-methylenandrosta-1,4-diene-3,17-dione) in the manufacture of a medicament for treating gastric cancer. 8. A pharmaceutical composition formulated and/or labeled for treating gastric cancer comprising exemestane (6-methylenandrosta-1,4-diene-3,17-dione) and a different gastric cancer drug, such as 5-FU (fluorouracil) or its analog capecitabine, BCNU (carmustine), methyl-CCNU (semustine), doxorubicin, mitomycin C, cisplatin and taxotere.
本部(發文號1100064602)同意貴校110年9月17日明產字第1100011381號函申請終止維護專利。(中國醫)
產學合作處生物科技發展育成中心
(04)2205-3366轉1581
版權所有 © 國家科學及技術委員會 National Science and Technology Council All Rights Reserved.
建議使用IE 11或以上版本瀏覽器,最佳瀏覽解析度為1024x768以上|政府網站資料開放宣告
主辦單位:國家科學及技術委員會 執行單位:台灣經濟研究院 網站維護:台灣經濟研究院